rivoglitazone (CS-011) / Daiichi Sankyo, Santen - LARVOL DELTA

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Jade Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Jade Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Jade Biosciences, Inc.

New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Jade Biosciences, Inc.

New P1 trial

20210096: Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-101) (clinicaltrialsregister.eu) - P2/3 | N=327 | Completed | Sponsor: Amgen Inc. | Active, not recruiting ➔ Completed

Trial completion • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Phase 1 Study of JADE101 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Jade Biosciences, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

Neuromodulation in Substance Use Disorders (clinicaltrials.gov) - P=N/A | N=20 | Active, not recruiting | Sponsor: Manish Ranjan | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Substance Abuse

A Phase 1 Study of JADE101 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Jade Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase 1 Study of JADE101 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Jade Biosciences, Inc.

New P1 trial

The association between circulating SIGLEC6 and preeclampsia: observational studies of seven cohorts. (PubMed, EBioMedicine) - "SIGLEC6 is elevated with preeclampsia and levels correlate with disease severity."

Journal • Observational data • Gynecology • Hepatology • Obstetrics

Neuromodulation in Substance Use Disorders (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Ali Rezai

New trial • Substance Abuse

Rural-urban differences in wait-time to general surgical outpatient care. (PubMed, Can J Rural Med) - "Les patients ruraux ont des temps d'attente pour les soins chirurgicaux significativement plus longs que leurs homologues urbains. Cet écart est plus prononcé chez les patients de la catégorie rurale R1 et chez les Māori et colons. Des mesures sont nécessaires pour améliorer l'accès à la chirurgie en milieu rural, telles que des cliniques spécialisées dans les zones rurales, de meilleurs services de transport hospitalier et des services de triage virtuels."

Journal

Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis. (PubMed, Indian J Endocrinol Metab) - "When compared to pioglitazone (30-45 mg/d), HbA1c lowering was comparable with standard-dose [MD 0.05%(95%CI:-0.01 - 0.11); P = 0.08; I = 11%], but superior with high-dose [MD -0.11%(95%CI:-0.18- -0.04); P < 0.01; I = 0%] rivoglitazone. Severe adverse events with standard-dose [RR1.88 (95%CI: 0.69-5.12);P = 0.22;I = 0%] and high-dose [RR 1.27 (95% CI: 0.45 - 3.59); P = 0.68; I = 0%] rivoglitazone was comparable to placebo. This meta-analysis highlights the good glycaemic efficacy and safety of both standard and high-dose rivoglitazone, and appears to be better than lobeglitazone in T2DM."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP

Asociación entre preocupación frente a la COVID-19, el apoyo social y el conocimiento sobre tuberculosis con el cumplimiento del tratamiento antituberculoso en Lima, Perú. (PubMed, Biomedica) - "El incumplimiento del tratamiento antituberculoso es una condición frecuente entre los pacientes de una zona de alta prevalencia de tuberculosis en Lima especialmente entre aquellos con mayor preocupación al contagio por el virus de SARSCoV-2, causante de la COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

"Aumentar plazas MIR,reducir la residencia....En Aragon hay un rechazo masivo a las plazas de Atencion Continuada(en llamamiento de interinidades reciente elegidas 12 plazas de 101 ofertadas) que seguiran vacantes si no se mejoran las condiciones,da igual el numero de aspirantes." (,@medicomadrid24h)

Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L. (PubMed, Pharmaceuticals (Basel)) - "Compared to the antidiabetic drug rivoglitazone, compound 3 acted as a potential PPAR-γ agonist with a binding energy of -7.4 kcal mol. Moreover, compound 8 displayed the strongest affinity, with binding energies of -6.9 kcal/mol to 5HT and -8.1 kcal/mol to 5HT, using serotonin and the antipsychotic drug risperidone as positive controls, respectively...The regression equation/correlation coefficient (r) for linolenic acid was Y = 6.49X + 2310.8/0.9971 in the linearity range of 100-1200 ng/band. The content of α-linolenic acid in S. irio aerial parts was found to be 28.67 μg/mg of dried extract."

Biomarker • Journal • CNS Disorders

"¡Austria🇦🇹 reaviva las odds y pasa de 101🔴 a 36🟢 en apena hora y media!🤩🔥 #ESC2023 https://t.co/WhdgPSD6Ms" (,@Sergio331)

Cardiovascular

MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands. (PubMed, PLoS One) - "We used HEKMOP/NOP cells and two bivalent ligands; Dermorphin-N/OFQ (MOP agonist-NOP agonist; DeNO) and Dermorphin-UFP101 (MOP agonist-NOP antagonist; De101)...We provide evidence for MOP-NOP interaction in recombinant and native tissue. NOP activation reduces responsiveness of MOP activation; this was shown with conventional and bivalent ligands."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Palliative care • Psychiatry

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrialsregister.eu) - P3; N=516; Ongoing; Sponsor: Amgen Inc.

Clinical • New P3 trial • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR2

Systemic and adipocyte transcriptional and metabolic dysregulation in Idiopathic Intracranial Hypertension. (PubMed, JCI Insight) - "These data show that IIH is a metabolic disorder in which adipose tissue dysfunction is a feature of the disease. Managing IIH as a metabolic disease could reduce disease morbidity and improving cardiovascular outcomes."

Journal • Cardiovascular • CNS Disorders • Genetic Disorders • Hypertension • Immunology • Metabolic Disorders • Obesity • Ophthalmology • LEP

"Victoria en Australie a réussi son confinement de 101 jours. @DrMikeRyan est tt content. That's one happy doc. 🤩" (,@CordayCharlot)

Efficacy and safety of rivoglitazone as monotherapy for type 2 diabetes mellitus (ADA 2010) - P=NA; N=1,912; At Wk 26, all active treatment groups demonstrated significant A1C reductions, while PBO showed a significant increase; RIVO 1.5mg was found to be non-inferior to PIO (p<0.0001)

Diabetes

Medical and Economic Impact of a Free Student-Run Podiatric Medical Clinic A Preliminary Analysis. (PubMed) - "These results suggest that the free student-run podiatric medical clinic at Clínica Tepati had a significant medical and economic impact on the delivery of health care at the regional level, and when extrapolated, nationally as well. These student-run clinics also play an important role in medical education settings."

Journal • Biosimilar

Detection of 549 new HLA alleles in potential stem cell donors from the United States, Poland and Germany. (PubMed) - HLA - "Some new alleles (55, 10.0%) were found multiple times, HLA-DPB1 alleles being the most frequent among these. Furthermore, as several new alleles were identified in individuals from ethnic minority groups, the relevance of recruiting donors belonging to such groups and the importance of ethnicity data collection in donor centers and registries is highlighted."

Journal • Biosimilar

Possible role of rivoglitazone thiazolidine class of drug as dual-target therapeutic agent for bacterial infections: An in silico study. (PubMed, Med Hypotheses) - "Further molecular dynamic (MD) simulations were performed to validate the stability of rivoglitazone/4MOT and rivoglitazone/4C13 complexes and to get insight into the binding mode of inhibitor. Thus, we hypothesize that structural modifications of the rivoglitazone scaffold can be useful for the development of an effective antibacterial agent."

Journal